$AVR News

Cantor Fitzgerald Reiterates Overweight on Anteris Technologies Glb, Maintains $15 Price Target

Reported Earlier, Anteris Technologies Glb Q2 EPS $(0.30) Misses $(0.21) Estimate, Sales $1.009M Miss $1.500M Estimate

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies Announces Results for the Second Quarter of 2026

TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next Challenge

France clearance marks key milestone for Anteris' pivotal PARADIGM Trial

Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance

Anteris Technologies Receives Full Regulatory Clearance From The French National Agency For Medicines And Health Products Safety For The DurAVR Transcatheter Heart Valve Global Pivotal Trial In Patients With Severe Calcific Aortic Stenosis

Anteris Technologies Global To Offer Up To $250M Of Common Stock Through TD Cowen

Barclays Maintains Overweight on Anteris Technologies Glb, Raises Price Target to $18

Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation

Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy

Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Glb Q1 EPS $(0.28) Misses $(0.27) Estimate, Sales $494.000K Miss $766.667K Estimate

Anteris treats first US patients in DurAVR pivotal trial

Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valve

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Global To Discontinue Development Contributions Under Agreement With v2vmedtech; Required To Pay $400,000 Break Fee To v2vmedtech; Expects No Material Adverse Effect From Agreement Termination